Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in pancreatic cancer
- Trial result
Pancreatic cancer
Motixafortide (CXCR4 inhibitor) + cemiplimab (PD-1) + gem/nab-paclitaxel posts 55% confirmed ORR in 1L metastatic PDAC
Motixafortide is a CXCR4 antagonist intended to disrupt the CXCR4/CXCL12-driven immune-excluded PDAC microenvironment, paired here with the PD-1 antibody cemiplimab plus gemcitabine/nab-paclitaxel (MCGN). In an…
NCT04543071 - Trial result
Pancreatic cancer
ACT (PS101 + focused ultrasound) plus mFOLFIRINOX shows early responses and a resection conversion signal in locally advanced/borderline PDAC
Acoustic Cluster Therapy (ACT) is an investigational ultrasound-mediated drug delivery approach in which IV PS101 (perfluorocarbon microbubbles/microdroplets) is activated by focused ultrasound to transiently…
NCT06850623 - Trial result
Pancreatic cancer
Atebimetinib (deep cyclic MEK inhibitor) + mGnP links weight preservation to longer OS in 1L pancreatic cancer
Atebimetinib is a MEK inhibitor developed to pair direct anti-tumor activity with mitigation of cancer cachexia/body-mass loss, and was evaluated with modified gemcitabine/nab-paclitaxel (mGnP) in first-line…
NCT07562152 - New trial
Pancreatic cancer
Phase 1/2 selumetinib plus trastuzumab deruxtecan targets KRAS-mutant, HER2-expressing pancreatic cancer
This NCI-sponsored Phase 1/2 study combines selumetinib (AZD6244, AstraZeneca), an oral MEK1/2 inhibitor, with trastuzumab deruxtecan (T-DXd, Daiichi Sankyo/AstraZeneca), a HER2-directed antibody-drug conjugate…
NCT07619521 Exploratory - New trial
Pancreatic cancer
Phase 1b/2 avutometinib plus defactinib adds RAF/MEK and FAK inhibition to mFOLFIRINOX in pancreatic cancer
This University of Virginia Phase 1b/2, open-label study adds avutometinib, a RAF/MEK pathway inhibitor often described as a RAF/MEK clamp, and defactinib, a focal adhesion kinase inhibitor, to modified FOLFIRINOX in…
NCT07824960 Exploratory - New trial
Pancreatic cancer
Phase 1 Lm-LLO-TT Listeria-based tetanus-toxoid cancer vaccine + gemcitabine in PDAC
This Phase 1, open-label, first-in-human dose-escalation study tests intraperitoneal (into the peritoneal cavity) Lm-LLO-TT plus low-dose gemcitabine in adults with previously treated unresectable or metastatic…
NCT07828236 First-in-human - New trial
Pancreatic cancer
Phase 1 repurposed pentamidine + mFOLFIRINOX in PDAC
University of Oklahoma is running this Phase 1, two-arm, first-line study in advanced/metastatic or unresectable locally advanced pancreatic ductal adenocarcinoma to compare modified FOLFIRINOX alone (oxaliplatin…
NCT07829185 Exploratory - New trial
Pancreatic cancer
Phase 1b/2 PRISM‑TAMP tests arterial gemcitabine chemotherapy microperfusion
University of Vermont is running this Phase 1b/2, single-arm, open-label study in borderline resectable pancreatic ductal adenocarcinoma to see whether adding trans-arterial microperfusion (TAMP) delivery of…
NCT07477418 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D RAS(ON) inhibitor + daraxonrasib (RMC-6236) RAS(ON) multi-selective inhibitor
Revolution Medicines’ RASolute 309 is a Phase 3, randomized, open-label study testing whether dual RAS(ON) blockade improves outcomes versus standard chemotherapy in first-line metastatic pancreatic adenocarcinoma…
NCT07805954 Registrational - Trial result Spotlight
Pancreatic cancer
L-Glutamine + Gem/Nab-P Reaches 22-Month mOS in Advanced PDAC
The Phase 1 GlutaPanc trial (NCT04634539) added oral L-glutamine—a metabolic intervention with preclinical evidence of sensitizing pancreatic cancer to chemotherapy—to first-line gemcitabine + nab-paclitaxel in…
NCT04634539 - Trial result
Pancreatic cancer
Personalized Neoantigen Vaccines Elicit T-Cell Responses in Resected PDAC, With 4.4-Year mOS
Two Phase 1 trials (NCT03956056 and NCT03122106) tested personalized synthetic long-peptide and DNA vaccines designed from each patient’s tumor neoantigens after pancreatic cancer surgery and adjuvant chemotherapy.…
NCT03956056 - New trial
Pancreatic cancer
Phase 2 telisotuzumab adizutecan (ABBV-400) c-Met/HGFR ADC with topoisomerase payload
AbbVie’s AndroMETa-118 (NCT07769502; AbbVie study M26-118) is a Phase 2, open-label master protocol in pancreatobiliary cancers testing telisotuzumab adizutecan (ABBV‑400), a c‑Met/HGFR–directed monoclonal…
NCT07769502 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 1b/2 ANO31905 CLDN18.2×CD3 bispecific + chemo in first-line PDAC
This open-label, nonrandomized Phase 1b/2 study (n=84) tests two dose levels of ANO31905 plus gemcitabine and nab-paclitaxel in untreated CLDN18.2-positive locally advanced unresectable or metastatic pancreatic…
NCT07444541 Exploratory - New trial
Pancreatic cancer
Phase 2 vilastobart tumor-activated Fc-enhanced anti-CTLA-4 plus retifanlimab PD-1 blockade in HRD PDAC.
This Phase 2, single-arm, open-label study (EKLAVYA-HRD) tests dual immune checkpoint blockade using vilastobart (XTX101)—a tumor-activated, Fc‑enhanced anti‑CTLA‑4 antibody designed to preferentially activate in the…
NCT07765836 Exploratory - New trial
Pancreatic cancer
Phase 2 SMART-PANC tests SMAD4-guided neoadjuvant chemo (DNA synthesis/tubulin inhibitors) in PDAC
Northwestern University is running this single-center, non-randomized Phase 2 pilot in resectable and borderline-resectable pancreatic ductal adenocarcinoma (PDAC) to see whether pre-treatment SMAD4 status can be…
NCT07748611 Exploratory - New trial
Pancreatic cancer
Phase 1 XNW28012 tissue factor–targeted topo1 inhibitor ADC in metastatic pancreatic cancer
Evopoint Biosciences’ Phase 1, open-label, randomized, multicenter study tests XNW28012 monotherapy in metastatic pancreatic cancer that has progressed after prior therapy, with two IV Q3W dose levels (2.0 mg/kg vs…
NCT07707674 Exploratory - Trial result
Pancreatic cancer
Maximal ablative RT (67.5Gy/15fx or 75Gy/25fx) + capecitabine enables 27% resection and 38% 2-year OS in vascular-encased LAPC
Hypofractionated ablative radiation therapy (A-RT)—dose-escalated external-beam RT (67.5Gy in 15 fractions or 75Gy in 25 fractions) with concurrent capecitabine—was tested in a single-arm Phase 2 MSK trial…
NCT03523312 - New trial Spotlight
Pancreatic cancer
Phase 2 ASP-1929 EGFR-targeted photoimmunotherapy (cetuximab–IR700 conjugate) in pancreatic cancer.
This open-label Phase 2 BrUOG 438 study tests ASP-1929 photoimmunotherapy (PIT) as a peri-operative, EGFR-targeted cytotoxic immune-activating approach for locally advanced or borderline resectable pancreatic…
NCT07698613 Exploratory - Trial result
Pancreatic cancer
Niraparib (PARP inhibitor) Delivers 4.4-mo mPFS in DDR-Altered Advanced Pancreatic Cancer (NIRA-PANC)
Niraparib is an oral PARP1/2 inhibitor tested as monotherapy in an open-label, single-arm Phase II study (NIRA-PANC; NCT03553004) for metastatic or unresectable pancreatic cancer with germline or somatic DDR…
NCT03553004 - New trial
Pancreatic cancer
Phase 1 ELI-002 7P KRAS-targeted amphiphile peptide vaccine with mFOLFIRINOX ± PD-1 blockade
This Memorial Sloan Kettering Cancer Center–led, open-label, multi-institution pilot study tests neoadjuvant mFOLFIRINOX (5-FU/leucovorin + irinotecan + oxaliplatin cytotoxic chemotherapy) combined with ELI-002 7P,…
NCT07671339 Exploratory - Trial result Spotlight
Pancreatic cancer
Atebimetinib (MEK deep cyclic inhibitor) + mGnP Delivers 42% ORR in 1L Metastatic PDAC
Atebimetinib is an oral next-generation MEK “deep cyclic inhibitor” (DCI) designed for pulsatile MAPK-pathway inhibition, and was combined with modified gemcitabine/nab-paclitaxel (mGnP; every-other-week dosing) in a…
NCT05585320 - Trial result Spotlight
Pancreatic cancer
Nesuparib (JPI-547) dual TNKS/PARP inhibitor + GemAbraxane hits 53.8% ORR in 1L advanced PDAC, but mFOLFIRINOX combo not tolerated
Nesuparib is an oral dual tankyrase (TNKS) and PARP inhibitor designed to induce “BRCAness” (via WNT/Hippo pathway modulation) and was combined with first-line GemAbraxane or modified FOLFIRINOX in a multicenter,…
NCT05257993 - Trial result Spotlight
Pancreatic cancer
Surufatinib (VEGFR/FGFR1/CSF1R TKI) + KN046 (PD-L1/CTLA-4 bispecific) + gem/nab-paclitaxel drives 71% ORR and 18.0-mo mOS in 1L advanced PDAC
Surufatinib is an oral multi-kinase inhibitor (VEGFR/FGFR1/CSF1R) with anti-angiogenic and macrophage-modulating activity, and KN046 is an IV PD-L1/CTLA-4 bispecific antibody designed to deliver dual checkpoint…
NCT05832892 - Trial result
Pancreatic cancer
Emavusertib (CA-4948) IRAK4/NF-κB Inhibitor + Gem/Nab-Paclitaxel Posts 20% ORR in 2L PDAC (Phase I)
Emavusertib (CA-4948) is an oral IRAK4 inhibitor designed to blunt pro-survival NF-κB signaling and potentially sensitize PDAC to cytotoxic chemotherapy; it is being dose-escalated with gemcitabine/nab-paclitaxel…
NCT05685602 - Trial result
Pancreatic cancer
NP137 (anti–netrin-1; EMT inhibitor) + mFOLFIRINOX Delivers 10.9-mo mPFS in 1L Locally Advanced PDAC
NP137 is a monoclonal antibody that neutralizes netrin-1 to inhibit epithelial-to-mesenchymal transition (EMT), combined here with modified FOLFIRINOX as first-line therapy in LAPNET-01, a single-arm Phase Ib study…
NCT06203821 - Trial result
Pancreatic cancer
Claude Opus 4.1 CA-EDA flags prior neurotoxic chemo as a pain-response predictor in celiac plexus radiosurgery
Conversational AI-assisted exploratory data analysis (CA-EDA) used three commercial LLMs (Claude Opus 4.1, ChatGPT 5.2, Gemini 3 Pro) to analyze raw individual patient data from a completed multicentre single-arm…
NCT03323489 - Trial result
Pancreatic cancer
Ibrilatazar (ABTL0812) autophagy inducer fails ITT PFS but trends to longer OS in ECOG 0 mPDAC
Ibrilatazar (ABTL0812) is a first-in-class oral agent designed to induce cytotoxic autophagy selectively in cancer cells; PanC-ASAP randomized first-line metastatic PDAC patients to ibrilatazar (1300mg TID) +…
NCT04431258 - Trial result
Pancreatic cancer
Olaparib + PD-1 blockade (pembrolizumab) misses PFS bar in gBRCA metastatic PDAC maintenance
SWOG S2001 (NCT04548752) randomized Phase II tested maintenance olaparib (PARP inhibitor) 300mg BID plus pembrolizumab (PD-1) Q3W vs olaparib alone in metastatic pancreatic ductal adenocarcinoma with germline BRCA1/2…
NCT04548752 - Trial result
Pancreatic cancer
Precemtabart tocentecan (M9140) anti-CEACAM5 TOP1 ADC posts 21.7% PR rate in pretreated mPDAC
Precemtabart tocentecan (Precem‑TcT, M9140) is an anti‑CEACAM5 antibody–drug conjugate delivering an exatecan (TOP1 inhibitor) payload; interim data come from the Phase 1b/2 open-label PROCEADE‑PanTumor PDAC substudy…
NCT06710132 - Trial result
Pancreatic cancer
MultiDom telemonitoring (circadian rhythm + ePRO) cuts emergency admissions to 3.8% during upfront mFOLFIRINOX in advanced PDAC
MultiDom (NCT04263948) is a prospective, multicentre, single-arm digital intervention layering continuous chest-sensor circadian monitoring (dichotomy index I<O), daily connected weight, and MDASI-based ePROs to…
NCT04263948
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.